Warning Letter Wednesday® Posts
A weekly exploration of FDA warning letters and enforcement trends
Takeaway -
Product names & images can communicate disease claims
Takeaway -
Submitting an NDI notification does not replace adequate safety support
Takeaway -
Review what your marketing implies, not just what it says
Takeaway -
Review website navigation, marketplace listings, and older social posts for compliance
Takeaway -
Ingredient studies may support carefully qualified claims
Takeaway -
Submitting an NDIN does not establish product safety
Takeaway -
Properly written SOPs are essential for compliance
Takeaway -
Support the exact claim consumers are likely to take away
Takeaway -
Review country-of-origin claims across all marketing
Takeaway -
Following good documentation practices is a cornerstone of compliance
Takeaway -
Review all marketing in context
Takeaway -
Review all marketing in context